top of page

REACT-EU invests in the next generation regenerative medicine production equipment of ReGEN Biomedical

12 dec. 2021

ReGEN Biomedical and Maastricht University have been granted 5.5 million euro from REACT-EU to realize an industrial sized regenerative medicine pilot line.

ReGEN Biomedical has the ambition to develop equipment to industrialize Regenerative Medicine (RM) manufacturing. Over the past years, Maastricht University has been able to fully commit to its knowledge in the field of RM and has built up an impressive IP portfolio for this purpose. ReGEN Biomedical is a collaborative vehicle to valorize this knowledge. The small-scale and labor-intensive procedures of the Maastricht University labs are converted into prototype machines and materials to serve the RM market in an industrial and large-scale manner. 

bottom of page